Ellen V. Sigal

1.7k total citations
23 papers, 405 citations indexed

About

Ellen V. Sigal is a scholar working on Oncology, Economics and Econometrics and Cancer Research. According to data from OpenAlex, Ellen V. Sigal has authored 23 papers receiving a total of 405 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Economics and Econometrics and 7 papers in Cancer Research. Recurrent topics in Ellen V. Sigal's work include Cancer Genomics and Diagnostics (7 papers), Health Systems, Economic Evaluations, Quality of Life (6 papers) and Economic and Financial Impacts of Cancer (5 papers). Ellen V. Sigal is often cited by papers focused on Cancer Genomics and Diagnostics (7 papers), Health Systems, Economic Evaluations, Quality of Life (6 papers) and Economic and Financial Impacts of Cancer (5 papers). Ellen V. Sigal collaborates with scholars based in United States, Canada and United Kingdom. Ellen V. Sigal's co-authors include Jeff Allen, Samantha Roberts, Jessica C. Walrath, Mark McClellan, Richard L. Schilsky, Aaron S. Kesselheim, Razelle Kurzrock, Hagop M. Kantarjian, Mark Stewart and Debra G. B. Leonard and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ellen V. Sigal

22 papers receiving 378 citations

Peers

Ellen V. Sigal

ONCOL

PRM

E.C. Faulkner United States

Gwynn Ison United States

Navdeep Pal United States

Thomas Gwise United States

Grace Hsu Canada

Joseph C. Del Paggio Canada

Mathias Lidgren Sweden

Ciska Verbaanderd Belgium

Helen M. Moore United States

NM Hylton United States

E.C. Faulkner United States

Ellen V. Sigal

135 ×1.0

153 ×1.5

ONCOL

76 ×0.8

121 ×1.5

77 ×1.4

PRM

Citations per year, relative to Ellen V. Sigal Ellen V. Sigal (= 1×) peers E.C. Faulkner

Countries citing papers authored by Ellen V. Sigal

Since Specialization

Citations

This map shows the geographic impact of Ellen V. Sigal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen V. Sigal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen V. Sigal more than expected).

Fields of papers citing papers by Ellen V. Sigal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen V. Sigal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen V. Sigal. The network helps show where Ellen V. Sigal may publish in the future.

Co-authorship network of co-authors of Ellen V. Sigal

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen V. Sigal. A scholar is included among the top collaborators of Ellen V. Sigal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen V. Sigal. Ellen V. Sigal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dragnev, Konstantin H., Mary W. Redman, Karen L. Reckamp, et al.. (2025). PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.. Journal of Clinical Oncology. 43(17_suppl).

Stewart, Mark, et al.. (2024). Bridging research and practice: enhancing regulatory decisions with pragmatic clinical trials in oncology. SHILAP Revista de lepidopterología. 6. 100065–100065. 1 indexed citations

Vaidya, Riha, Joseph M. Unger, Katherine Minichiello, et al.. (2023). Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). JCO Precision Oncology. 7(7). e2300218–e2300218. 1 indexed citations

Herbst, Roy S., Charles D. Blanke, & Ellen V. Sigal. (2023). Novel Approach to Accelerate Lung Cancer Research: Lung-MAP and the Potential of Public-Private Partnerships. Clinical Cancer Research. 30(1). 29–32. 3 indexed citations

Stewart, Mark, et al.. (2020). A National Assessment of Diagnostic Test Use for Patients with Advanced NSCLC and Factors Influencing Physician Decision-Making.. PubMed Central. 13(3). 110–119. 4 indexed citations

Stewart, Mark, Lisa H. Butterfield, Bruce L. Levine, et al.. (2020). Accelerating the development of innovative cellular therapy products for the treatment of cancer. Cytotherapy. 22(5). 239–246. 7 indexed citations

Kurzrock, Razelle, Hagop M. Kantarjian, Aaron S. Kesselheim, & Ellen V. Sigal. (2020). New drug approvals in oncology. Nature Reviews Clinical Oncology. 17(3). 140–146. 34 indexed citations

Redman, Mary W., Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, et al.. (2020). Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).. Journal of Clinical Oncology. 38(15_suppl). 9576–9576. 1 indexed citations

Stewart, Mark, et al.. (2019). How Oncologists Perceive the Availability and Quality of Information Generated From Patient-Reported Outcomes (PROs). SHILAP Revista de lepidopterología. 7(2). 217–224. 2 indexed citations

10.

Stewart, Mark, et al.. (2018). Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice. Therapeutic Innovation & Regulatory Science. 52(6). 771–777. 9 indexed citations

11.

Allen, Jeff, Mark Stewart, Samantha Roberts, & Ellen V. Sigal. (2017). The Value of Addressing Patient Preferences. Value in Health. 20(2). 283–285. 23 indexed citations

12.

Roberts, Samantha, et al.. (2016). Impact of breakthrough therapy designation on cancer drug development. Nature Reviews Drug Discovery. 15(3). 152–152. 30 indexed citations

13.

Glass, Daniel, et al.. (2016). Use of FDA-approved vs. lab-developed tests in advanced non-small cell lung cancer.. Journal of Clinical Oncology. 34(15_suppl). e20532–e20532. 2 indexed citations

14.

Anderson, Margaret, Gail H. Cassell, Lynn R. Goldman, et al.. (2015). Mission Possible: How FDA Can Move at the Speed of Science. PDXScholar (Portland State University). 3 indexed citations

15.

McClellan, Mark & Ellen V. Sigal. (2015). The 21st Century Cures Act.. New England Journal of Medicine. 373(17). 1677–8. 14 indexed citations

16.

Horning, Sandra J., Daniel A. Haber, Wendy Selig, et al.. (2013). Developing Standards for Breakthrough Therapy Designation in Oncology. Clinical Cancer Research. 19(16). 4297–4304. 24 indexed citations

17.

Hayes, Daniel F., Jeff Allen, Carolyn C. Compton, et al.. (2013). Breaking a Vicious Cycle. Science Translational Medicine. 5(196). 196cm6–196cm6. 90 indexed citations

18.

Fridlyand, Jane, Richard Simon, Jessica C. Walrath, et al.. (2013). Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nature Reviews Drug Discovery. 12(10). 743–755. 54 indexed citations

19.

Roberts, Samantha, Jeff Allen, & Ellen V. Sigal. (2011). Despite Criticism Of The FDA Review Process, New Cancer Drugs Reach Patients Sooner In The United States Than In Europe. Health Affairs. 30(7). 1375–1381. 54 indexed citations

20.

Schilsky, Richard L., Jeff Allen, Joshua S. Benner, Ellen V. Sigal, & Mark McClellan. (2010). Commentary: Tackling the Challenges of Developing Targeted Therapies for Cancer. The Oncologist. 15(5). 484–487. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact